Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NPCE
stocks logo

NPCE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
24.43M
+13.81%
-0.186
+3.11%
22.35M
-0.79%
-0.185
-11.71%
23.09M
-1.84%
-0.163
-37.32%
Estimates Revision
The market is revising No Change the revenue expectations for NeuroPace, Inc. (NPCE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 74.41%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+74.41%
In Past 3 Month
Wall Street analysts forecast NPCE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NPCE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast NPCE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NPCE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.970
sliders
Low
16.00
Averages
18.00
High
20.00
Current: 16.970
sliders
Low
16.00
Averages
18.00
High
20.00
JPMorgan
NULL -> Overweight
maintain
$16 -> $18
2025-11-05
Reason
JPMorgan
Price Target
$16 -> $18
2025-11-05
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on NeuroPace to $18 from $16 and keeps an Overweight rating on the shares. The company reported a Q3 "beat and raise," the analyst tells investors in a research note.
H.C. Wainwright
initiated
$18
2025-05-28
Reason
H.C. Wainwright
Price Target
$18
2025-05-28
initiated
Reason
H.C. Wainwright initiated coverage of NeuroPace with a Buy rating and $18 price target. NeuroPace is a commercial-stage medical device company focused on the development and marketing of a brain-responsive neuromodulation system that can deliver personalized, real-time treatment at the seizure source for patients with drug-resistant focal epilepsy, the analyst tells investors in a research note. The firm says the cutback after the one-year data readout from the NAUTILUS study presents an attractive entry point, as the data have no impact on the sales momentum in patients with focal epilepsy.
JPMorgan
Overweight
maintain
$14 -> $16
2025-05-13
Reason
JPMorgan
Price Target
$14 -> $16
2025-05-13
maintain
Overweight
Reason
JPMorgan raised the firm's price target on NeuroPace to $16 from $14 and keeps an Overweight rating on the shares. The company reported good Q1 results ahead of the Street, with gross margin and revenue topping estimates and operating expense coming in lower, the analyst tells investors in a research note. This was another strong quarter for NeuroPace, with healthy contribution from Project Care, record new prescribers, and sustained utilization across Level 4 centers, the firm added.
Cantor Fitzgerald
Ross Osborn
Buy
Maintains
$19 → $20
2025-03-05
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$19 → $20
2025-03-05
Maintains
Buy
Reason
Wells Fargo
Larry Biegelsen
Buy
Maintains
$13 → $17
2025-01-30
Reason
Wells Fargo
Larry Biegelsen
Price Target
$13 → $17
2025-01-30
Maintains
Buy
Reason
Wells Fargo raised the firm's price target on NeuroPace to $17 from $13 and keeps an Overweight rating on the shares. The firm notes NeuroPace laid out its strategy and LRP at its investor day on January 28. Wells views its new multiple as appropriate given solid management execution and recent beat and raises.
UBS
Priya Sachdeva
Strong Buy
Initiates
$17
2025-01-21
Reason
UBS
Priya Sachdeva
Price Target
$17
2025-01-21
Initiates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Neuropace Inc (NPCE.O) is -25.78, compared to its 5-year average forward P/E of -8.79. For a more detailed relative valuation and DCF analysis to assess Neuropace Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.79
Current PE
-25.78
Overvalued PE
-2.84
Undervalued PE
-14.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-13.74
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-2.41
Undervalued EV/EBITDA
-25.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.10
Current PS
0.00
Overvalued PS
6.76
Undervalued PS
1.45
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

NPCE News & Events

Events Timeline

(ET)
2025-11-24
08:10:52
NeuroPace Reveals Increased Medicare Reimbursement for RNS System
select
2025-11-04 (ET)
2025-11-04
16:52:46
NeuroPace Announces Q3 Earnings Per Share of 11 Cents, Below Consensus Estimate of 19 Cents
select
2025-08-12 (ET)
2025-08-12
16:24:11
NeuroPace raises FY25 revenue view to $94M-$98M, consensus $94.78M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-02Newsfilter
NeuroPace Showcases RNS System Advances, Enhancing Epilepsy Treatment
  • Clinical Outcomes Showcase: NeuroPace will present new clinical data on the RNS System at the 2025 American Epilepsy Society Annual Meeting, emphasizing its effectiveness in reducing seizures, which is expected to attract more physician interest and drive product adoption.
  • AI-Driven Tool Development: The company will unveil next-generation NeuroPace AI and SeizureID™ tools, designed to transform intracranial EEG data into actionable insights, thereby streamlining epilepsy care processes and enhancing clinical decision-making confidence.
  • NAUTILUS Trial Results: Updated data from the NAUTILUS clinical trial will showcase 18-month safety and efficacy outcomes for idiopathic generalized epilepsy, further validating the therapeutic potential of the RNS System, which may enhance market recognition of this therapy.
  • Leading Scientific Presentations: NeuroPace will feature over 80 scientific presentations and posters at the meeting, making it the company with the most presentations in neuromodulation therapy, underscoring its leadership position in the epilepsy treatment field.
[object Object]
Preview
9.5
11-09NASDAQ.COM
Transcript of NeuroPace (NPCE) Earnings Call for Q3 2025
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
2.0
11-06Benzinga
Major Stocks on the Rise Wednesday: Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical, and More

  • U.S. Stock Market Performance: U.S. stocks rose, with the Nasdaq Composite gaining over 200 points, driven by strong earnings reports from several companies.

  • Johnson Controls International Results: Johnson Controls International PLC reported fourth-quarter earnings of $1.26 per share and revenue of $6.44 billion, exceeding analyst expectations, leading to an 8% increase in its stock price.

  • Significant Stock Gains: Other notable stock performances included Solid Power Inc (up 55.7%), Babcock & Wilcox Enterprises Inc (up 38.8%), and Neuropace Inc (up 38.3%), all reporting better-than-expected quarterly results.

  • Broad Market Reactions: Several companies, including Teva Pharmaceutical Industries Ltd and Digital Turbine Inc, also saw significant stock price increases after surpassing earnings expectations and raising future sales guidance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Neuropace Inc (NPCE) stock price today?

The current price of NPCE is 16.97 USD — it has increased 1.86 % in the last trading day.

arrow icon

What is Neuropace Inc (NPCE)'s business?

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.

arrow icon

What is the price predicton of NPCE Stock?

Wall Street analysts forecast NPCE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NPCE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Neuropace Inc (NPCE)'s revenue for the last quarter?

Neuropace Inc revenue for the last quarter amounts to 27.35M USD, increased 29.89 % YoY.

arrow icon

What is Neuropace Inc (NPCE)'s earnings per share (EPS) for the last quarter?

Neuropace Inc. EPS for the last quarter amounts to -0.11 USD, decreased -42.11 % YoY.

arrow icon

What changes have occurred in the market's expectations for Neuropace Inc (NPCE)'s fundamentals?

The market is revising No Change the revenue expectations for NeuroPace, Inc. (NPCE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 74.41%.
arrow icon

How many employees does Neuropace Inc (NPCE). have?

Neuropace Inc (NPCE) has 184 emplpoyees as of December 05 2025.

arrow icon

What is Neuropace Inc (NPCE) market cap?

Today NPCE has the market capitalization of 565.23M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free